Version history

{
  "description": "Falsifiable prediction from high-scoring hypothesis (score=0.724, gene=TARDBP). Hypothesis: Does TDP-43 liquid-liquid phase separation (LLPS) state — measured by FRAP — predict therapeutic response to nuclear import receptor (IPO4/IPO9) treatment in ALS/FTD neurons? Success criteria: 1. FRAP recovery half-time of TDP-43-eGFP is >3× slower in ALS/FTD patient iPSC neurons vs controls. 2. IPO4/IPO9 treatment (10μM, 72h) increases nuclear TDP-43 by >40% (nuclear/cytoplasmic ratio by IF). 3. IPO4 treatment restores FRAP recovery to within 20% of control values in ALS neurons. 4. Nuclear pore integrity marker (mAb414) increases by >30% after IPO4 treatment, validated by EM.",
  "challenge_type": "hypothesis_resolve",
  "scope": "single_target",
  "initial_bounty_usd": 500,
  "current_bounty_usd": 500,
  "bounty_confidence": 0.5,
  "market_price": 0.5,
  "composite_score": 0.72407,
  "debate_count": 0,
  "status": "open",
  "question": "Does TDP-43 liquid-liquid phase separation (LLPS) state — measured by FRAP — predict therapeutic response to nuclear import receptor (IPO4/IPO9) treatment in ALS/FTD neurons?",
  "domain": "neurodegeneration",
  "triggered_by": "hypothesis-auto-create"
}